Kim N Chi

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. doi request reprint Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer
    Emma K Beardsley
    BC Cancer Agency, Vancouver, Canada
    Curr Opin Support Palliat Care 2:161-6. 2008
  2. doi request reprint A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
    K N Chi
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver Department of Urologic Sciences, Vancouver Prostate Center, University of British Columbia, Vancouver, Canada
    Ann Oncol 27:1116-22. 2016
  3. pmc A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
    K N Chi
    Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
    Ann Oncol 27:454-60. 2016
  4. doi request reprint Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
    K N Chi
    British Columbia Cancer Agency, Vancouver, BC, Canada
    Cancer Chemother Pharmacol 71:237-44. 2013
  5. doi request reprint A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer
    Kim N Chi
    Vancouver Prostate Centre, Vancouver, British Columbia, Canada
    Clin Cancer Res 18:3407-13. 2012
  6. doi request reprint A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
    K N Chi
    Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, Vancouver, BC, Canada
    Ann Oncol 23:53-8. 2012
  7. ncbi request reprint A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
    K N Chi
    Vancouver Cancer Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    Clin Cancer Res 7:3920-7. 2001
  8. doi request reprint Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer
    Kim N Chi
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 28:4247-54. 2010
  9. doi request reprint Castration-resistant prostate cancer: from new pathophysiology to new treatment targets
    Kim N Chi
    BC Cancer Agency, Vancouver, British Columbia, Canada
    Eur Urol 56:594-605. 2009
  10. doi request reprint A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer
    Kim N Chi
    British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:833-9. 2008

Collaborators

Detail Information

Publications62

  1. doi request reprint Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer
    Emma K Beardsley
    BC Cancer Agency, Vancouver, Canada
    Curr Opin Support Palliat Care 2:161-6. 2008
    ..The purpose of this article is to review recent developments in this area...
  2. doi request reprint A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
    K N Chi
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver Department of Urologic Sciences, Vancouver Prostate Center, University of British Columbia, Vancouver, Canada
    Ann Oncol 27:1116-22. 2016
    ..Apatorsen (OGX-427) is a 2'-methoxyethyl-modified antisense oligonucleotide that inhibits Hsp27 expression. This study evaluated the safety profile and recommended phase II dosing of apatorsen in patients with advanced cancer...
  3. pmc A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
    K N Chi
    Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
    Ann Oncol 27:454-60. 2016
    ..We developed a prognostic index model using readily available clinical and laboratory factors from a phase III trial of abiraterone acetate (hereafter abiraterone) in combination with prednisone in post-docetaxel mCRPC...
  4. doi request reprint Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
    K N Chi
    British Columbia Cancer Agency, Vancouver, BC, Canada
    Cancer Chemother Pharmacol 71:237-44. 2013
    ..To assess the effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan HBr (CYP2D6 substrate) and theophylline (CYP1A2 substrate) in patients with metastatic castration-resistant prostate cancer (mCRPC)...
  5. doi request reprint A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer
    Kim N Chi
    Vancouver Prostate Centre, Vancouver, British Columbia, Canada
    Clin Cancer Res 18:3407-13. 2012
    ..This study evaluated biologic and clinical effects of figitumumab, a fully human monoclonal IGF-IR antibody, in patients with localized prostate cancer...
  6. doi request reprint A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
    K N Chi
    Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, Vancouver, BC, Canada
    Ann Oncol 23:53-8. 2012
    ..The purpose of this study was to determine the clinical activity of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel...
  7. ncbi request reprint A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
    K N Chi
    Vancouver Cancer Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    Clin Cancer Res 7:3920-7. 2001
    ..In this dose escalation study, we evaluated the combination of Genasense and mitoxantrone, a standard chemotherapy for patients with HRPC...
  8. doi request reprint Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer
    Kim N Chi
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 28:4247-54. 2010
    ..To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer...
  9. doi request reprint Castration-resistant prostate cancer: from new pathophysiology to new treatment targets
    Kim N Chi
    BC Cancer Agency, Vancouver, British Columbia, Canada
    Eur Urol 56:594-605. 2009
    ..Castration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited...
  10. doi request reprint A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer
    Kim N Chi
    British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:833-9. 2008
    ..The objective of this study was to determine a recommended phase II dose of OGX-011 in combination with docetaxel...
  11. ncbi request reprint A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
    K N Chi
    Department of Medical Oncology, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia
    Ann Oncol 19:746-51. 2008
    ..The purpose of this trial was to evaluate the antitumor activity of sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, in patients with castration-resistant prostate cancer...
  12. ncbi request reprint A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer
    Kim N Chi
    Vancouver Cancer Centre, BC Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada
    J Natl Cancer Inst 97:1287-96. 2005
    ..The primary objective of this clinical study was to determine a biologically effective dose of OGX-011 that would inhibit clusterin expression in human cancer...
  13. ncbi request reprint A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer
    Kim N Chi
    BC Cancer Agency, Vancouver, British Columbia, Canada
    Invest New Drugs 23:311-5. 2005
    ..Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg...
  14. ncbi request reprint Antisense approaches in prostate cancer
    Kim N Chi
    BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada
    Expert Opin Biol Ther 4:927-36. 2004
    ....
  15. ncbi request reprint Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer
    Kim N Chi
    BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada
    World J Urol 23:33-7. 2005
    ..Randomized trials are required to determine if oblimersen can enhance the effectiveness of docetaxel in patients with HRPC...
  16. doi request reprint Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer
    Kim N Chi
    Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro Oncology Group, Vancouver, British Columbia, Canada
    J Urol 180:565-70; discussion 570. 2008
    ..We assessed pathological outcomes as well as the feasibility of combined docetaxel and androgen deprivation therapy in men with prostate cancer before undergoing prostatectomy...
  17. doi request reprint A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
    Emma K Beardsley
    BC Cancer Agency Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Invest New Drugs 30:1652-9. 2012
    ..The objective of this trial was to evaluate the clinical effects of sorafenib, a multi-targeted kinase inhibitor, in combination with androgen receptor blockade in patients with castration-resistant prostate cancer...
  18. doi request reprint Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
    Daniel Y C Heng
    FRCPC, Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
    J Clin Oncol 27:5794-9. 2009
    ..There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF) -targeted therapy...
  19. ncbi request reprint Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia
    Abdulwahab J Al-Tourah
    Vancouver Cancer Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
    J Urol 174:2209-13, discussion 2213. 2005
    ....
  20. doi request reprint Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status
    Arun A Azad
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Eur Urol 67:441-7. 2015
    ....
  21. ncbi request reprint Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer
    Bernhard J C Eigl
    The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
    Clin Cancer Res 11:4905-11. 2005
    ..We explored the hypothesis that stress-induced gene expression changes after chemotherapy can induce a hormone-independent phenotype...
  22. doi request reprint Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery
    Christian Kollmannsberger
    Division of Medical Oncology, British Columbia Cancer Agency Vancouver Cancer Centre, British Columbia, Canada
    J Clin Oncol 28:537-42. 2010
    ..The current study assesses the outcome for a modern, unselected patient population with disseminated testicular cancer with particular emphasis on those achieving a radiographic complete remission to combination chemotherapy...
  23. doi request reprint A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer
    Arun A Azad
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Prostate 74:1544-50. 2014
    ..We investigated whether the biochemical response to abiraterone is associated with efficacy of subsequent docetaxel therapy...
  24. ncbi request reprint Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers
    Martin Gleave
    Division of Urology, University of British Columbia, The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia V5Z 3J5, Canada
    Ann N Y Acad Sci 1058:1-15. 2005
    ....
  25. doi request reprint A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer
    Daniel Y C Heng
    Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Cancer 115:776-83. 2009
    ..This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients...
  26. ncbi request reprint Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)
    Sunil Parimi
    Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada
    Invest New Drugs 34:771-776. 2016
    ..Conclusion Sunitinib was tolerable as maintenance therapy but median PFS was significantly lower than the predefined threshold of 6 months...
  27. doi request reprint Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients
    Arun A Azad
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Eur Urol 67:23-9. 2015
    ..However, limited data are available on the efficacy of enzalutamide following abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC)...
  28. doi request reprint A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer
    Arun A Azad
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada
    Invest New Drugs 32:746-52. 2014
    ....
  29. doi request reprint Targeting the apoptosis pathway in prostate cancer
    Robert R Zielinski
    BC Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    Cancer J 19:79-89. 2013
    ....
  30. doi request reprint Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer
    Robert Zielinski
    Bristish Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada
    Future Oncol 8:1239-51. 2012
    ..These studies not only have the potential to significantly alter the standard of care in prostate cancer, but would also endorse a new class of targets and targeted therapy approach for cancer...
  31. ncbi request reprint A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer
    Anna Tinker
    BC Cancer Agency, Vancouver, BC, Canada
    Am J Clin Oncol 29:3-7. 2006
    ..The aim of this study was to determine the toxicity and phase II dose of a triplet regimen of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell carcinoma...
  32. ncbi request reprint Prednisone monotherapy in asymptomatic hormone refractory prostate cancer
    Daniel Y C Heng
    Department of Medical Oncology, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Can J Urol 13:3335-9. 2006
    ..Prednisone has been used in this setting; however, limited data is available for this monotherapy in the asymptomatic HRPC population...
  33. ncbi request reprint A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131
    K A Gelmon
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC
    Ann Oncol 15:1115-22. 2004
    ..To assess its potential combined with a taxane, a phase I study of AMD473 and docetaxel in advanced cancer was initiated by the National Cancer Institute of Canada-Clinical Trials Group...
  34. ncbi request reprint The standard of reporting of health-related quality of life in clinical cancer trials
    C W Lee
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Epidemiol 53:451-8. 2000
    ..The standard of reporting of randomized controlled trials (RCTs) is important to the interpretation of outcomes such as health-related quality of life (HRQL). HRQL is used increasingly as an outcome in clinical cancer trials...
  35. doi request reprint AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate
    Tilman Todenhöfer
    Vancouver Prostate Centre, University of British Columbia, British Columbia, Vancouver, Canada Department of Urology, University Hospital, Tubingen, Germany
    J Urol . 2016
    ....
  36. pmc Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
    Nada Lallous
    Vancouver Prostate Centre, University of British Columbia, 2660 Oak St, Vancouver, BC, V6H 3Z6, Canada
    Genome Biol 17:10. 2016
    ..In order to develop an effective CRPC therapy, it is crucial to understand the effects of these mutations on the functionality of the AR and its ability to interact with endogenous steroids and conventional AR inhibitors...
  37. pmc Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
    Alexander W Wyatt
    Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    JAMA Oncol 2:1598-1606. 2016
    ..Although tissue biopsies are impractical to perform routinely in the majority of patients with mCRPC, the analysis of plasma cell-free DNA (cfDNA) has recently emerged as a minimally invasive method to explore tumor characteristics...
  38. doi request reprint Targeting heat shock proteins in metastatic castration-resistant prostate cancer
    Arun A Azad
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada
    Nat Rev Urol 12:26-36. 2015
    ..As a consequence, HSPs represent highly attractive targets in the development of treatments for CRPC...
  39. ncbi request reprint Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer
    Kim N Chi
    The Prostate Centre at Vancouver General Hospital, 6th Floor, 2775 Laurel Street, Vancouver, V5Z 1M9, British Columbia, Canada
    Expert Opin Investig Drugs 17:1955-62. 2008
    ..Custirsen (OGX-011) is a 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA; it is currently in clinical trials for patients with cancer...
  40. doi request reprint A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer
    J Michels
    Department of Medical Oncology, Vancouver Centre, British Columbia Cancer Agency, Vancouver, Canada
    Ann Oncol 21:305-11. 2010
    ....
  41. doi request reprint Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer
    Kim N Chi
    BC Cancer Agency, Vancouver, BC, Canada
    J Clin Pharmacol 55:1406-14. 2015
    ..Adverse events (all grade ≤ 3) were similar, with high-fat/low-fat meals or fasted/modified fasting state. Short-term dosing with food did not alter abiraterone acetate safety...
  42. pmc PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
    Jennifer L Bishop
    Vancouver Prostate Centre, Vancouver, BC, Canada
    Oncotarget 6:234-42. 2015
    ..immune cell PD-L1 expression in progression of CRPC to anti-androgen resistance and the utility of monitoring circulating cell PD-L1 pathway activity in CRPC patients to predict responsiveness to checkpoint immunotherapy, is warranted...
  43. pmc Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada
    Reka Pataky
    Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, Canada
    Int J Cancer 135:939-47. 2014
    ..Screening may be cost-effective, but the sensitivity of results to utility values suggests individual preferences for quality versus quantity of life should be a key consideration. ..
  44. pmc Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer
    Akira Watahiki
    The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC V6H 3Z6, Canada
    Int J Mol Sci 14:7757-70. 2013
    ..Our results demonstrate that plasma levels of selected miRNAs are potential biomarkers to differentiate localized PCa and mCRPC...
  45. pmc Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions
    Daniel Y C Heng
    BC Cancer Agency, 600 West 12 Avenue, Vancouver, British Columbia, V5Z 4E6, Canada
    Ther Adv Med Oncol 2:39-49. 2010
    ..Sequential and combination targeted therapies are currently under investigation in advanced disease as are adjuvant and neo-adjuvant approaches around nephrectomy...
  46. doi request reprint Novel targeted therapies for prostate cancer
    Robyn J Macfarlane
    Division of Medical Oncology, BC Cancer Agency Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
    Urol Clin North Am 37:105-19, Table of Contents. 2010
    ..There has also been interest generated by data from early-phase studies evaluating multitargeted tyrosine kinase inhibitors, agents effecting signal transduction pathways, and novel cytotoxics...
  47. ncbi request reprint Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer
    Ada Man
    Department of Radiation and Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6
    J Urol 170:901-4. 2003
    ..We compared survival outcomes in patients of Asian descent treated with curative intent radiation therapy for prostate cancer with that in the nonAsian population in British Columbia, Canada...
  48. doi request reprint Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
    Daniel P Petrylak
    Daniel P Petrylak, Yale University Cancer Center, New Haven, CT Scott T Tagawa, Weill Cornell Medical College, New York David Shaffer, New York Oncology Hematology, Albany, NY Manish Kohli, Mayo Clinic, Rochester, MN Andrea Eisen, Sunnybrook Health Sciences Centre Srikala S Sridhar, Princess Margaret Hospital, Toronto Christina Canil, Ottawa Hospital Cancer Centre, Ottawa, Ontario Kim N Chi, British Columbia Cancer Agency, Vancouver, British Columbia, Canada Alexander Spira, Virginia Cancer Specialists, Fairfax, VA Alexander Spira, John M Burke, David Shaffer, and Nicholas J Vogelzang, US Oncology Research, The Woodlands, TX Evan Y Yu, University of Washington Medical Center and Fred Hutchinson Cancer Research Center, Seattle, WA John M Burke, Rocky Mountain Cancer Centers, Aurora, CO Chong Xian Pan, University of California Davis Medical Center, Massachusetts 02181
    J Clin Oncol 34:1500-9. 2016
    ....
  49. doi request reprint Chemotherapy for metastatic castration-sensitive prostate cancer
    Sunil Parimi
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Int J Urol 23:726-33. 2016
    ..Three randomized phase III trials have defined the benefits of docetaxel in the metastatic castration-sensitive prostate cancer setting; however, there remain questions and controversies on the appropriate and optimal patient selection. ..
  50. ncbi request reprint Carboplatin and vinblastine for the treatment of metastatic transitional cell carcinoma of the urothelial tract
    Huda A Al-Karim
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
    Am J Clin Oncol 25:515-9. 2002
    ..The combination of carboplatin and vinblastine given in this schedule is a feasible, well-tolerated, and active alternative for patients with metastatic TCC unfit for standard chemotherapy...
  51. ncbi request reprint High dose calcitriol may reduce thrombosis in cancer patients
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Br J Haematol 135:392-4. 2006
    ..In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans...
  52. ncbi request reprint Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    J Clin Oncol 25:669-74. 2007
    ..To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel...
  53. ncbi request reprint Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
    Guru Sonpavde
    Genitourinary Oncology Program, U S Oncology Research, Houston, Texas, USA
    Cancer 110:2628-39. 2007
    ..Recent and ongoing studies of neoadjuvant therapy followed by prostatectomy were reviewed...
  54. ncbi request reprint Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    N Engl J Med 351:1502-12. 2004
    ..We compared such treatment with docetaxel plus prednisone in men with this disease...
  55. ncbi request reprint Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer 112:326-30. 2008
    ..In the current study, the authors examined retreatment with the same regimen after a treatment holiday...
  56. doi request reprint C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Sciences University, Portland, OR 97239, USA
    Cancer 112:2377-83. 2008
    ..The authors sought to determine whether specific blood proteins associated with inflammation predict for outcomes in men with metastatic androgen-independent prostate cancer (AIPC) who are initiating docetaxel-based chemotherapy...
  57. ncbi request reprint A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer
    Eric Winquist
    London Regional Cancer Centre, London, Ontario, Canada
    Urol Oncol 23:143-9. 2005
    ....